Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2407
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study ; volume:19 ; number:1 ; day:25 ; month:3 ; year:2019 ; pages:1-10 ; date:12.2019
BMC cancer ; 19, Heft 1 (25.3.2019), 1-10, 12.2019

Creator
Parsons, Janet A.
Greenspan, Nicole R.
Baker, Natalie A.
McKillop, Chris
Hicks, Lisa K.
Chan, Olivia
Contributor
SpringerLink (Online service)

DOI
10.1186/s12885-019-5467-x
URN
urn:nbn:de:101:1-2019041621335689581949
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:58 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Parsons, Janet A.
  • Greenspan, Nicole R.
  • Baker, Natalie A.
  • McKillop, Chris
  • Hicks, Lisa K.
  • Chan, Olivia
  • SpringerLink (Online service)

Other Objects (12)

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Management of Relapsed and Refractory Multiple Myeloma: Recent advances

Management of Relapsed and Refractory Multiple Myeloma: Recent advances

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel

Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel

Related objects